Carella A M, Santini G, Martinengo M, Giordano D, Nati S, Congiu A, Cerri R, Risso M, Damasio E, Rossi E
Cancer. 1985 Apr 1;55(7):1452-4. doi: 10.1002/1097-0142(19850401)55:7<1452::aid-cncr2820550705>3.0.co;2-d.
Twenty-five adults with previously treated acute leukemia were treated with 4-demethoxydaunorubicin (Idarubicin) with a daily dose of 8 mg/m2 for 3 days intravenously. Complete remission was achieved in 3 of 18 patients with acute nonlymphoblastic leukemia (ANLL) and 2 of 6 with lymphoblastic leukemia. Complete remissions were observed in two of eight ANLL patients refractory to cytarabine, anthracycline, and m-Amsa (amsacrine), indicating a lack of cross-resistance between these drugs and Idarubicin. The median duration of remission was 8 weeks. The main major toxicity of Idarubicin therapy, severe myelosuppression, cannot be considered a toxic effect because it was desired in this case list. Our preliminary results indicate that Idarubicin has significant activity against refractory adult acute leukemia.
25例曾接受过治疗的成年急性白血病患者接受了4-去甲氧柔红霉素（伊达比星）治疗，静脉注射，每日剂量8mg/m²，持续3天。18例急性非淋巴细胞白血病（ANLL）患者中有3例、6例淋巴细胞白血病患者中有2例达到完全缓解。在8例对阿糖胞苷、蒽环类抗生素和m-安吖啶（安吖啶）耐药的ANLL患者中，有2例观察到完全缓解，表明这些药物与伊达比星之间不存在交叉耐药性。缓解期的中位数为8周。伊达比星治疗的主要毒性，即严重的骨髓抑制，在本病例中不能被视为毒性作用，因为这是预期的。我们的初步结果表明，伊达比星对难治性成人急性白血病具有显著活性。
